Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Clinical Trials Search Results
Query: "AREA[SponsorSearch](Allist Pharmaceuticals, Inc.)"
|NCT04958967||Phase Ib Study of FURMONERTINIB in Patients With NSCLC Having Exon 20 Insertion Mutation (FAVOUR1)|
|NCT04858958||Study of FURMONERTINIB in Patients With NSCLC Having Exon 20 Insertion Mutation|
|NCT04853342||To Assess the Efficacy and Safety of Furmonertinib Versus Placebo, in Patients With Epidermal Growth Factor Receptor Mutation Positive Stage II-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy|
|NCT03941340||Study Evaluating the Mass Balance And Biotransformation of Single Dose[14C] AST2818 in Chinese Healthy Male Volunteers|
|NCT03926182||Study to Determine the Effect of Food on the Blood Levels of AST2818 Following Single Oral Doses in Healthy Male Volunteers|
|NCT03787992||Alflutinib Mesylate Versus Gefitinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer （FLAG）|
|NCT03452592||Efficacy and Safety of Alflutinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer Patients With T790M|
|NCT03127449||AST2818 in Advanced Non-Small Cell Lung Cancer With EGFR Mutations|
|NCT02973763||Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of Alflutinib in Advanced Non Small Cell Lung Cancer|
|NCT04965831||Furmonertinib as Perioperation Therapy in Stage IIIA-IIIB (N1-N2) Resectable EGFR Mutated Lung Adenocarcinoma (FRONT)|
|NCT04895930||Furmonertinib Combined With Anlotinib as the First-line Treatment in Patients With EGFR Mutation-positive NSCLC|